On Tuesday, Pfizer Inc stated that a large study to test its COVID-19 vaccine in children below 12 and selected a dosing regime for the trial will start. The company said that the study will be registering up to 4,500 children at more than 90 clinical sites in the United States, Finland, Poland and Spain.
In Europe, the United States and Canada, the Pfizer’s vaccine has been authorized for children as young as 12. A selective dosage of 10 micrograms in children between 5 and 11 years of age and 3 micrograms for infants in the age-group of 6 months to five have been planned for the vaccine dose.
The Inoculation for children and young people is considered as a critical step toward reaching “herd immunity” and curbing the COVID-19 pandemic.